Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Omadacycline Tosylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 55,459Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Paratek Ph 2b Data Shows Omadacycline’s Potential in NTM Treatment
    Paratek Ph 2b Data Shows Omadacycline’s Potential in NTM Treatment

    15 Nov 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/paratek-phase-iib-data-shows-omadacyclines-potential-to-address-unmet-needs-in-ntm-treatment-says-globaldata/

    EXPRESSPHARMA
    15 Nov 2024
    Share Share
    Paratek Completes U.S. Onshoring for NUZYRA Domestic Supply
    Paratek Completes U.S. Onshoring for NUZYRA Domestic Supply

    14 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/14/2981251/0/en/Paratek-Pharmaceuticals-Announces-Completion-of-U-S-Onshoring-Program-Making-NUZYRA-omadacycline-the-Only-Novel-Antibiotic-with-Domestic-Supply-and-Manufacturing-Capabilities.html

    GLOBENEWSWIRE
    14 Nov 2024
    Share Share
    Paratek Pharma Positive Phase 2b Omadacycline NTM Data
    Paratek Pharma Positive Phase 2b Omadacycline NTM Data

    08 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/08/2977671/0/en/Paratek-Pharmaceuticals-Announces-Positive-Top-Line-Data-from-Phase-2b-Study-of-Oral-Omadacycline-OMC-in-Nontuberculous-Mycobacterial-NTM-Abscessus-Pulmonary-Disease.html

    GLOBENEWSWIRE
    08 Nov 2024
    Share Share
    Paratek Announces Presentation of Studies of Nuzyra at IDWeek 2024
    Paratek Announces Presentation of Studies of Nuzyra at IDWeek 2024

    14 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/14/2962469/0/en/Paratek-Pharmaceuticals-Announces-Presentation-of-Several-New-Studies-of-NUZYRA-omadacycline-Across-a-Range-of-Serious-Infections-at-IDWeek-2024.html

    GLOBENEWSWIRE
    14 Oct 2024
    Share Share
    Paratek Completes 5-Year NUZYRA® Surveillance Study
    Paratek Completes 5-Year NUZYRA® Surveillance Study

    31 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/31/2921773/0/en/Paratek-Pharmaceuticals-Completes-Five-Year-Microbiologic-Surveillance-Study-of-NUZYRA-omadacycline-Demonstrating-No-Change-in-In-Vitro-Potency-Against-Indicated-Pathogens.html

    GLOBENEWSWIRE
    31 Jul 2024
    Share Share
    Paratek Reports Positive Data For NUZYRA In Bacterial Pneumonia Study
    Paratek Reports Positive Data For NUZYRA In Bacterial Pneumonia Study

    18 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/18/2915177/0/en/Paratek-Pharmaceuticals-Announces-Positive-Top-line-Efficacy-and-Safety-Data-from-Post-Marketing-Study-of-NUZYRA-omadacycline-for-Patients-with-Moderate-to-Severe-Community-Acquire.html

    GLOBENEWSWIRE
    18 Jul 2024
    Share Share